New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
11:41 EDTOREX, IDIX, BDSI, NSR, MONT, ULTA, LULU, OPEN, RHOptions with decreasing implied volatility
Options with decreasing implied volatility: OREX IDIX BDSI NSR MONT ULTA LULU OPEN RH HSH
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:17 EDTNSRNeuStar raises FY14 adjusted EPS view to $4.08-$4.25 from $3.88-$4.05
Subscribe for More Information
16:16 EDTNSRNeuStar raises FY14 outlook
16:15 EDTNSRNeuStar reports Q3 adjusted EPS $1.37, consensus $1.04
Reports Q3 revenue $243.9M, consensus $243.24M.
October 28, 2014
10:30 EDTLULUlululemon may have another PR issue on hand, says Sterne Agee
Subscribe for More Information
08:04 EDTBDSIBioDelivery Sciences to develop opioid dependence injection with Evonik
Subscribe for More Information
October 27, 2014
16:45 EDTMONTGLG Partners reports 5.53% passive stake in Montage Technology
Subscribe for More Information
October 23, 2014
09:13 EDTMONTMontage Technology receives NASDAQ extended stay
Montage Technology announced that on October 21, the company received a letter from The NASDAQ Stock Market indicating that, pursuant to a request submitted by the company on October 8, the Nasdaq Hearings Panel has granted the company's request to extend the automatic 15-day stay of suspension of trading in the company's ordinary shares pending the hearing on the merits of the company's appeal scheduled for November 6 and a final determination regarding the company's listing status thereafter. The company plans to provide an update regarding its continued listing on NASDAQ once a decision has been issued by the Panel.
October 22, 2014
15:27 EDTLULUlululemon management to meet with William Blair
Subscribe for More Information
04:57 EDTLULUlululemon partners with Dalai Lama Center
Subscribe for More Information
October 20, 2014
08:08 EDTOREXOrexigen and Takeda announce availability of Contrave tablets for patients
Takeda Pharmaceutical, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A. and Orexigen Therapeutics jointly announced that Contrave extended-release tablets are now available to patients by prescription in pharmacies across the U.S.. Contrave is approved by the FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use